NCT06885021

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 780 (estimated)
• Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Conditions

• Overweight and Obesity

Interventions

Type	Name	Description
DRUG	HDM1002 200mg, oral, once daily, 52 weeks	HDM1002 200mg, oral, once daily, 52 weeks
DRUG	HDM1002 400mg, oral, once daily, 52 weeks	HDM1002 400mg, oral, once daily, 52 weeks
DRUG	HDM1002 placebo, oral, once daily, 52 weeks	HDM1002 placebo, oral, once daily, 52 weeks

Timeline

• Start date: 2025-03-28
• Primary completion: 2026-05-30
• Completion: 2026-06-30
• First posted: 2025-03-19
• Last updated: 2025-03-19